Anti-estrogens, as the name suggests, are drugs that counteract or suppress the activity of estrogen in the body.
These anti-estrogens can be naturally derived substances (like plant or herb extracts) or synthetic drugs created in a lab, and they are primarily divided into two main categories: Aromatase Inhibitors (AIs) and Selective Estrogen Receptor Modulators (SERMs).
Both Aromatase Inhibitors (AIs) and SERMs are used to mitigate or control estrogen-related issues.
AIs work by lowering the body’s total circulating plasma estrogen levels, while SERMs function by blocking the action of estrogen in specific tissues.
These two types of anti-estrogens are also utilized during Post Cycle Therapy (PCT) to aid in testosterone recovery after an anabolic steroid cycle.
They are widely used as drugs that specifically help restore endogenous testosterone production.
Over time, some of these anti-estrogens have also been found to be effective in treating hormonal disorders in men, such as hypogonadism.
However, it’s important to remember that the original purpose for developing most anti-estrogens was to treat estrogen-responsive breast cancer in women.
Confusion about the differences between AIs and SERMs is common among beginners new to anabolic steroids, but their functions are distinctly different.
AIs inhibit estrogen synthesis to reduce estrogen levels in the blood, whereas SERMs act selectively by blocking estrogen activation in specific tissues (e.g., breast tissue).
Aromatase Inhibitors (AIs)
Aromatase inhibitors are anti-estrogenic drugs used to suppress the production of estrogen in the body.
The three main compounds—Arimidex (Anastrozole), Femara (Letrozole), and Aromasin (Exemestane)—are the most widely used and effective.
Among the various aromatase inhibitors, which range from synthetic to naturally occurring compounds, these are particularly highly regarded in medicine.
Aromatase inhibitors work by inhibiting the action of the aromatase enzyme, which plays a crucial role in converting androgens into estrogens.
The enzyme’s substrate binding site is where the target molecule for a chemical reaction binds; in the case of aromatase, aromatizable androgens like testosterone are the substrate.
Aromatase inhibition is achieved through two methods: allosteric inhibition and competitive inhibition.
In allosteric inhibition, the aromatase inhibitor binds to the enzyme’s allosteric site, changing the shape of the substrate binding site and preventing the substrate from binding.
In contrast, competitive inhibition is a method where the inhibitor binds directly to the enzyme’s substrate binding site, blocking the substrate’s access.
There are also two types of aromatase inhibition: reversible inhibition and irreversible inhibition (suicide inhibition).
Reversible inhibitors, like Arimidex (Anastrozole) and Femara (Letrozole), temporarily bind to the aromatase enzyme to induce inhibition and eventually dissociate from it, allowing androgens to be aromatized again.
On the other hand, Aromasin (Exemestane) is an irreversible inhibitor, or a suicide inhibitor; it binds to the enzyme and permanently deactivates it, keeping estrogen production impossible until the body produces new enzymes.
Interestingly, Aromasin is classified as a steroidal aromatase inhibitor, while Arimidex and Femara act as non-steroidal compounds.
Because these aromatase inhibitors block the root cause of estrogen production in the body, they serve as powerful anti-estrogenic agents that effectively reduce circulating plasma levels of estrogen.
Selective Estrogen Receptor Modulators (SERMs)
Selective Estrogen Receptor Modulators (SERMs) belong to the oldest group of anti-estrogenic drugs, with notable examples including Nolvadex (Tamoxifen Citrate), Clomiphene Citrate (Clomid), Raloxifene, and Toremifene.
SERMs have the unique property of selectively modulating estrogen receptors distributed in various tissues of the body.
Interestingly, although SERMs are classified as anti-estrogens, they act as estrogen receptor agonists in some tissues and as antagonists in others.
For example, SERMs bind to estrogen receptors in the liver and increase estrogenic activity, but in the hypothalamus or breast tissue, they act as estrogen antagonists, reducing estrogen activity in those areas.
The way SERMs act as estrogen antagonists in the hypothalamus and breast tissue is by binding to estrogen receptors and keeping them in an inactive state.
This prevents circulating estrogen from binding to the receptors occupied by the SERM, which exerts an effect of preventing or reducing gynecomastia in breast tissue.
It also activates the negative feedback loop in the hypothalamus, stimulating the release of GnRH, which in turn increases testosterone production via the pituitary gland.
Another important characteristic of SERMs is that they do not reduce circulating blood estrogen levels but only inhibit estrogenic activity in specific tissues.
Due to this property, SERMs are not effective at reducing estrogen-related side effects like bloating or water retention, but they can provide powerful assistance in preventing gynecomastia or restoring testosterone.
SERMs are used as essential ancillary drugs in fields like bodybuilding, playing a crucial role in Post Cycle Therapy (PCT) or in specific situations by regulating the body’s estrogen balance and preventing side effects in targeted tissues. [1],[2]
Medical References
[1] Riggs BL, Hartmann LC (2003).
“Selective Estrogen-Receptor Modulators — Mechanisms of Action and Application to Clinical Practice”.
N Engl J Med 348 (7): 618–29.
doi:10.1056/NEJMc030651. PMID 12584371.
[2] Vermeulen A, Comhaire F. Fertil Steril.
Hormonal effects of the anti-oestrogen, tamoxifen, in normal and oligospermic men.
1978 Mar.
29(3):320-7.
